Roche drug reported to set new treatment standard for KRAS-driven non-small-cell lung cancer

STAT News reports that a Roche therapeutic has demonstrated efficacy in KRAS-mutant non-small-cell lung cancer (NSCLC) sufficient to be characterised as establishing a new standard of care in this molecularly defined subgroup. The lede of STAT's broader industry digest also notes activity from Vertex in gene therapy and signals of broader strength in the biotech sector.

KRAS is among the most frequently mutated oncogenes in human cancer, and somatic KRAS variants in lung, pancreatic, and colorectal cancers have historically been considered difficult to target pharmacologically. The emergence of direct KRAS inhibitors — beginning with the FDA approval of sotorasib in 2021 — has changed the therapeutic landscape; the Roche drug appears to represent a further development in this space, though full trial data and regulatory submissions were not detailed in the reporting available.

The content in question is behind a STAT+ paywall, limiting the depth of detail available from the lede alone. The KRAS story is of interest to oncologists and cancer-genetics researchers tracking how somatic genomic characterisation of tumours is shaping treatment decisions, and to educators and students studying the translation of cancer genomics into targeted therapy. Germline KRAS variants are also associated with RASopathies, though this report pertains to somatic tumour biology.